Research

Longevity Science: Capital, Claims, and Clinical Evidence

Longevity science is experiencing a surge of private capital into biological age-reversal technologies, but the clinical evidence base remains thin: no intervention has demonstrated dramatic human lifespan extension in a controlled trial, epigenetic clocks are unvalidated as clinical tools across diverse populations, and long-term safety data for leading drug candidates simply does not exist. The most robustly evidenced contributors to healthy lifespan remain unglamorous public-health measures — smoking reduction, blood pressure control, sanitation — while low-cost structural interventions in Kerala, Cuba, and Rwanda have achieved substantial gains at a fraction of longevity biotech costs, findings almost entirely absent from mainstream discourse. The central unresolved tension is whether private capital concentration accelerates genuinely beneficial innovation or distorts research agendas toward elite consumers and short VC return horizons, crowding out population-level needs — a dispute that turns on values and institutional design as much as on data.